February 15, 2010 (Vol. 30, No. 4)
Vi Chu Ph.D. R&D manager EMD Millipore
Review of Opportunities and Challenges in this Rapidly Expanding Field of Study
The ability to reprogram somatic cells to generate induced pluripotent stem (iPS) cells has generated tremendous interest and discussion since iPS cells were first produced from mouse cells in 2006 and human cells in 2007.
The reversion of differentiated cells to a state resembling embryonic stem cells offers a wealth of opportunities for disease researchers. Interest in iPS cells is expanding rapidly beyond the domain of stem cell experts to researchers modeling complex diseases in vitro and pursuing novel therapeutics.
With iPS cell technology, you can now take a skin biopsy from a patient with a genetic disease such as familial Alzheimer or Lou Gehrig disease and turn their somatic cells into stem cells, explains Chad Cowan, Ph.D., of the Harvard Stem Cell Institute. You can then take those stem cells and turn them into cell types that might be affected in the disease.
Along with the opportunities offered by iPS cells, practical challenges still abound. Culturing stem cells relies on both science and art and defining just what exactly constitutes a stem or iPS cell is stimulating a good deal of discussion.
Having standards for iPS cells could help define the differences between these murine embryonic stem cells and their induced counterparts.
Dr. Cowans lab is using iPS cells to support studies of obesity and metabolic disorders. While the lab can easily obtain fat cells from patients, these cells cant be cultured over the long term. We can keep the fat cells alive for a short period of time but that only allows us to do a one-time endpoint assay. It doesnt allow us to tease out the complexities of what might be going wrong in a patient with a metabolic disorder. The ability to make patient-specific fat cells from iPS cells completely changes the game.
With iPS cells, the lab can conduct dozens of assays to identify differences in fat cells from a person with a metabolic disorder such as type 2 diabetes versus a person with normal body weight or someone without diabetes. The ability to take a single genotype and potentially make any of the tissues that might be involved in a metabolic disorder such as hypothalamus, pancreatic beta cells, and hepatocytes, could lead to powerful disease models.
In his lab at the University of California, Santa Barbara, Dennis Clegg, Ph.D., is using iPS cells as one tool to study the loss of vision in age-related macular degeneration (AMD). In AMD, the degeneration of retinal pigment epithelial (RPE) cells appears to cause the death of neighboring rods and cones in the macular region of the central retina.
Dr. Cleggs lab is evaluating the use of iPS-derived RPE cells to treat AMD and using iPS cell lines to create ocular cells, which can be used to study how the eye develops. The real utility of iPS cells is that you can study human cells and processes in ways you couldnt do before, notes Dr. Clegg.
iPS cells, in particular those that are human-derived, can be challenging to culture especially for those researchers who havent previously worked with stem cells. The challenges they present are similar to those encountered when culturing human embryonic stem cells, including:
For researchers who havent previously cultured stem cells, I suggest first working with mouse-derived iPS cells. These cells tend to be more robust than human cells and conditions for successful culture are well defined. Many researchers first test their hypotheses using mouse iPS cells and then transition to a human model system.
The technology to create iPS cells is evolving rapidly. The first studies reporting the creation of iPS cells used retroviral vectors to integrate a set of DNA transcription factors directly into the somatic cell genome. Upon activation, these genes convert the cells from their adult, differentiated status to an embryonic-like state. This process required multiple retroviral vectors in order to insert four different viruseseach vector delivering one reprogramming gene into the somatic cells DNA.
Since these first studies were published, researchers have been seeking ways to reprogram somatic cells without using retroviral vectors and avoiding use of transcription factors such as c-Myc that are known oncogenes. Viral delivery of transcription factors can also disrupt normal gene expression when the vectors integrate into the genome. The high number of genomic integrations15 to 20that typically occur when multiple viruses are used for reprogramming poses a safety risk if the cells are to be used for therapeutic purposes.
Recently, Boston University scientists developed a highly efficient method for creating iPS cells from mouse fibroblasts using a single viral vector instead of the multiple viruses typically required for reprogramming. Four commonly used vectors are incorporated into a single lentiviral vector containing all four genes.
If iPS cells are to be used for therapeutic purposes, permanent integration of transcription factors into the genome becomes a problem. Alternative approaches to reprogramming include use of adenoviral delivery as the adenovirus does not integrate into the genome and transient transfection with transcription factors. Ultimately, it may be possible to use proteins or small molecules to direct the reprogramming process.
The rapid development and continued evolution of iPS technology has sparked discussions about the need for establishing standards to guide the field.
As researchers seek new methods to create iPS cells without genetic modification and the use of these cells to develop disease models continues to expand rapidly, questions arise as to whether these cells have the same properties and potential as embryonic stem cells. How can a researcher know for certain that he or she has generated iPS cells? Is there a minimum set of criteria for assessing whether a somatic cell is fully pluripotent or only partially reprogrammed?
Adding to this complexity, researchers also seek to understand the variation between iPS cell lines derived from a common somatic source.
Dr. Cleggs lab is looking at the similarities and differences between iPS cell lines derived from human fetal RPE cells. The question we were trying to address, describes Dr. Clegg, is if we take those cells down to iPS cells and just let them spontaneously differentiate, will they have some sort of epigenetic memory and tend to re-differentiate back into RPE or something else?
The first line we looked at snapped back in large quantities to RPE cells, reports Dr. Clegg. But each subsequent line we looked at was different. Thats an important lesson for people to understandeach iPS line thats generated is slightly different, just like each embryonic stem cell line is slightly different. They have different propensities for differentiation. They may have different epigenetics. They may have different expression patterns.
Were still learning to define what is the best iPS cell, notes Dr. Cowan. The best function identically to an embryonic stem cell. It remains pluripotent, expands, and self-renews and it can differentiate into the types of tissues youre interested in.
An article by Maherali and Hochedlinger (Cell Stem Cell Protocol Review, December 4, 2008) suggests a minimal set of criteria that should be fulfilled in order to ascertain that a genuine iPS cell has been generated. The criteria include:
With human iPS cells, pluripotency can be assessed based on teratoma formation, which is a specific type of tumor containing cells from all three germ layers.
Researchers are also probing the similarity of iPS cell and embryonic cells through microarray studies, high-throughput sequencing, assessment of DNA methylation status at pluripotent cell specific genes, and by examining a range of protein biomarkers.
As our understanding of the similarities and differences between iPS cells and embryonic stem cells grows, new tools to identify and compare these cell types are needed. For example, live-cell imaging can be used to distinguish between human iPS cells and partially reprogrammed cells.
While standards provide a good basis of comparison, Dr. Cowan suggests that standards can be restrictive. The standards are naturally evolving. We certainly need to maintain a minimum standard and recognize the standard will change over time. Within a year or two, there will probably be a new set of guidelines available. But there may be times when you may not want to make something that is an embryonic cell.
In fact, it may be more to your advantage to somehow uniquely trap a cell so that it is lineage-committed to something that can replicate in culture indefinitely but really only thinks of itself as lung, for example, and so would only ever differentiate back to lung cell types.
While a great deal remains to be learned about iPS cells, they represent a powerful new research tool. In addition to their potential impact on the field of regenerative medicine, use of iPS cells to dissect complicated diseases at the cellular level will provide valuable new insights supporting drug discovery. As we learn more about the nature of iPS cells, standards will certainly evolve and new tools will become available to facilitate efficient creation and routine culture.
Vi Chu, Ph.D. (email@example.com), is R&D manager, stem cell/cell biology at Millipore.
Here is the original post:
Induced Pluripotent Stem Cell Overview - genengnews.com
- Growing Value of Stem Cells in Medicine to Create a US$2,4 Billion Opportunity for Induced Pluripotent Stem Cell ((iPSC) - GlobeNewswire - November 27th, 2020
- Induced Pluripotent Stem Cells Market New Research Study Report with Size, Share, Trends, Emerging Applications, Opportunities and Worldwide Analysis... - November 27th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market Applications, Types and Future Ou - News by aeresearch - November 27th, 2020
- Research Paper Showing ProtoKinetix AAGP Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision - Business Wire - November 27th, 2020
- Induced Pluripotent Stem Cells Market 2020: Enhanced Growth, Recent Trends and Major Companies are Fujifilm Holding Corporation, Astellas Pharma, Fate... - November 27th, 2020
- The Stem Cell-Derived Cells market to Scale new heights in the next decade - Khabar South Asia - November 27th, 2020
- Astronaut Soichi Noguchi still adapting to life on ISS - The Japan Times - November 27th, 2020
- Potential new therapies for Alzheimer's disease are revealed through network modeling of its complex molecular interactions - Science Codex - November 27th, 2020
- Global Induced Pluripotent Market To Perceive Biggest Trend And Opportunity With Key Players CELGENE CORPORATION; Astellas Pharma Inc.; Thermo Fisher... - November 22nd, 2020
- Global Stem Cell Banking Market 2020: Overview, Trends, Opportunities, Impact of Drivers, Key Vendors, Types, Applications, Forecast by Focusing... - November 22nd, 2020
- Thanyapura, StemCells21 to offer premium stem cell treatments in Thailand - BSA bureau - November 20th, 2020
- Neurons stripped of their identity are hallmark of Alzheimer's disease, study finds - National Science Foundation - November 20th, 2020
- Fred Hutch at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more - Newswise - November 20th, 2020
- Stem Cells Market Value Expected To Reach $17.79 Billion By 2027 - Eurowire - November 20th, 2020
- How regenerative medicine could be used to contain COVID-19, others - Guardian - November 20th, 2020
- The Induced Pluripotent Stem Cells Market To Witness Fierce Competition Amongst The Key Players - KYT24 - November 18th, 2020
- at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more - Fred Hutch News Service - November 18th, 2020
- Neurons stripped of their identity are hallmark of Alzheimers disease, study finds - Newswise - November 18th, 2020
- Genetic influences on viral-induced cytokine responses in the lung - DocWire News - November 18th, 2020
- Japanese and U.S. astronauts arrive at ISS in SpaceX ship - The Japan Times - November 18th, 2020
- AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update - BioSpace - November 18th, 2020
- Coadministration of endothelial and smooth muscle cells derived from human induced pluripotent stem cells as a therapy for critical limb ischemia -... - November 12th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market Size, Drivers, Potential Growth Opportunities, Competitive Landscape, Trends And Forecast To 2027 -... - November 12th, 2020
- Proteintech and HebeCell Announce Collaboration on Nanobody iPSC-derived Natural Killer Cells - BioSpace - November 12th, 2020
- Global Induced Pluripotent Stem Cells Market Analysis Trends, Growth Opportunities, Size, Type, Dynamic Demand and Drives with Forecast to 2026 -... - November 12th, 2020
- Stem Cell Manufacturing Market Share & Size, Future Growth, Trends Evaluation, Demands, Regional Analysis and Forecast to 2027| Merck Group,... - November 12th, 2020
- Induced Pluripotent Stem Cells Market Comprehensive Insights, Growth, Forecast and Covid-19 Impact by 2026 | Medipost Co. Ltd., Ocata Therapeutics... - November 12th, 2020
- Induced Pluripotent Stem Cells Industry Market 2020 Global Trends, Key Players, Share, Growth, Analysis, Opportunities and Forecast To 2026 -... - October 31st, 2020
- The Stem Cell-Derived Cells market to be in conjunction to growth from 2020 to 2030 - PRnews Leader - October 31st, 2020
- In Vitro Toxicology Testing Market: Facts, Figures and Analytical Insights, 2018 to 2024 - Aerospace Journal - October 31st, 2020
- Bayer Acquires AskBio to Expand Gene Therapy Platform - PharmaLive - October 31st, 2020
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 with COVID-19 After Effects Growth Drivers, Top Key Players, Industry Segments and Forecast... - October 29th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By... - October 29th, 2020
- Global Induced Pluripotent Stem Cells Market Analysis by Size: 2025, Impact of Covid-19 on Industry Chain, Market Growth, Drivers | Business Overview... - October 29th, 2020
- The Induced Pluripotent Stem Cells Market To Witness A Major Breakthrough In The Form Of A Double-Digit CAGR Of 7% - KYT24 - October 29th, 2020
- Emulate Signs Collaborative Agreement with the FDA to Apply Lung-Chip to Evaluate Safety of COVID-19 Vaccines and Protective Immunity Against... - October 29th, 2020
- QurAlis Announces Appointment of New Chief Medical Officer and Formation of Clinical Advisory Board - BioSpace - October 29th, 2020
- AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute... - October 29th, 2020
- Bayer Acquires AskBio for Up to $4 Billion to Expand Gene Therapy Platform - BioSpace - October 29th, 2020
- How Will the Virus Epidemic Cause Induced Pluripotent Stem Cells (iPSCs) Market 2020 - The Think Curiouser - October 24th, 2020
- Trends in the Ready To Use Induced Pluripotent Stem Cells Market 2020-2020 - Eurowire - October 24th, 2020
- Stem Cell-Derived Cells Market to Expand at a Healthy CAGR of XX% Between and 2019 2029 - Eurowire - October 24th, 2020
- The Induced Pluripotent Stem Cells Market To Mark Robustness In The Form Of A Robust CAGR - KYT24 - October 23rd, 2020
- COVID-19 can affect the heart - Science Magazine - October 23rd, 2020
- Kobe Hospital Trials Transplant to Reverse Blindness A First in the World - JAPAN Forward - October 23rd, 2020
- Rethinking the Link between Cannabinoids and Learning - Lab Manager Magazine - October 23rd, 2020
- Cold sore virus can spread to unborn babies harming their brains, docs warn - The Sun - October 23rd, 2020
- Microscopy Beyond the Resolution Limit - Lab Manager Magazine - October 21st, 2020
- AMSBIO Launches New Human iPSC-Derived Cells and iPSC Differentiation Reagent Kits - Technology Networks - October 20th, 2020
- Induced Pluripotent Stem Cells Market To Grow At 7% YOY In Forecast Years 2026 - The Think Curiouser - October 20th, 2020
- Groundbreaking eye surgery in Kobe offers hope to sight impaired : The Asahi Shimbun - Asahi Shimbun - October 20th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Industry 2020 Includes The Major Application Segments And Size In The Global Market To 2026 - PRnews Leader - October 16th, 2020
- Induced Pluripotent Stem Cells Market 2020 Is Slated to Grow Rapidly in the Forthcoming Years with Key Players Addgene, Axol Bioscience, Cell... - October 16th, 2020
- Disruptive Technologies and Mature Regulatory Environment Vital for Cell Therapy Maturation - BioSpace - October 16th, 2020
- Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome... - October 16th, 2020
- Brain organoids reveal neuronal flaws in syndrome tied to autism - Spectrum - October 16th, 2020
- Manufacturing a Personalized Cellular Universe: 3D Bioprinting in the Biotech Industry - BioSpace - October 16th, 2020
- Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting - GlobeNewswire - October 16th, 2020
- Global Stem Cell Therapy Market 2020: Trends, and Opportunity Analysis, Top Manufacturers And Forecast to 2027 - PRnews Leader - October 16th, 2020
- Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients |... - October 8th, 2020
- Dolly the Sheep: '90s Media Sensation - Mental Floss - October 8th, 2020
- Regeneron, Pfizer and BioNTech Accused of Infringing Allele Patent in Connection with COVID-19 Technologies - IPWatchdog.com - October 8th, 2020
- Yufan inks deal with Abound to develop antibodies directing CAR T cells against cancer targets - BioWorld Online - October 7th, 2020
- Allele Biotechnology and Pharmaceuticals Files Two Lawsuits for Patent Infringement for the Unauthorized Use of mNeonGreen in Development and Testing... - October 7th, 2020
- Huge Investment in Induced Pluripotent Stem Cells Market Expected to Witness the Highest Growth 2026 | Fujifilm Holding Corporation (CDI) Ncardia,... - October 3rd, 2020
- Stem Cell-Derived Cells Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 - 2029 - Stock Market Funda - October 3rd, 2020
- Kyoto University project aims to supply iPS cells widely at low cost - The Japan Times - September 29th, 2020
- ONLINE: The Future of Medicine - Isthmus - September 29th, 2020
- funded study sheds light on abnormal neural function in rare genetic disorder - National Institutes of Health - September 29th, 2020
- Stem Cell Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily Chronicle - September 29th, 2020
- The new pharma collaborations driving transformative research in oncology - - pharmaphorum - September 29th, 2020
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 Manufacturer Analysis, Technology Advancements, Industry Scope and Forecast to 2027||Fate... - September 21st, 2020
- Induced Pluripotent Stem Cells Market to Witness Huge Growth by 2025| Bone Therapeutics SA, System Biosciences, Axiogenesis, Regeneus Ltd.,... - September 14th, 2020
- Global Stem Cells Market Report, History And Forecast 2020-2027, Breakdown Data By Manufacturers, Key Regions, Types And Application - Bulletin Line - September 11th, 2020
- New DNA Recovery Technique Reveals Richer Picture of the Past - Lab Manager Magazine - September 11th, 2020
- Study Identifies New Set of Genes That May Explain Why People with Down Syndrome Have a Higher Risk of Leukemia - DocWire News - September 10th, 2020
- Patenting Stem Cell Inventions in India- What to Expect? - Lexology - September 10th, 2020
- Scientists May Have Discovered a Way to to Slow Aging by Direct Reprogramming of Human Cells - SciTechDaily - September 10th, 2020
- Induced Pluripotent Stem Cells Market Global Growth Analysis and Forecast to 2024 | Top Players (BlueRock Therapeutics, Corning Life Sciences, EMD... - September 10th, 2020
- Study: The Speed Neurons Fire Impacts Their Ability to Synchronize - Lab Manager Magazine - September 10th, 2020